Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

New World Health Organisation (WHO) recommendations for the use of long-acting HIV prevention and treatment are a welcome boost in the global efforts to end ...